Get the Latest Investment Ideas Delivered Straight to Your Inbox. Subscribe

News Update


Biotech's Antibodies Target Toxic Oligomers Implicated in Parkinson's Disease
News Update

Share on Stocktwits


Testing conducted as part of this Canadian company's research and development work on Parkinson's disease therapeutics has identified new potential antibody candidates.

ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) has identified several targets displayed on toxic oligomers of alpha-synuclein, a protein believed to be a root cause of Parkinson's disease, and generated antibodies that protected brain neurons against those oligomers in vitro.

"I expect further development of these antibody candidates will offer real hope for disease-modifying therapy in Parkinson's disease," Dr. James Kupiec, ProMIS' chief medical officer, said in a news release.

The in vitro research involved testing ProMIS antibodies on rat primary dopaminergic neurons that had been exposed to toxic alpha-synuclein oligomers and consequently injured. The work was performed by Neuron Experts, a contract research organization in Marseilles, France.

A number of ProMIS antibodies that selectively target toxic alpha-synuclein oligomers "significantly blocked the death of neurons induced by these oligomers," noted the release.

The next steps are for ProMIS to corroborate the findings and choose the candidates with the most potential for development.

Because the Parkinson's disease program is "an ideal pharma partnering opportunity," according to ProMIS Executive Chairman Eugene Williams, the company retained Cambridge, Mass.-based Red Sky Partners to support those efforts.


1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article, until one week after the publication of the interview or article.

Want to read more about Biotechnology / Pharmaceuticals investment ideas?
Get Our Streetwise Reports Newsletter Free and be the first to know!

A valid email address is required to subscribe